Clinical Survey of Tizanidine-induced Adverse Effects -Impact of Concomitant Drugs Providing Cytochrome P450 1A2 Modification-
Clinical Survey of Tizanidine-induced Adverse Effects -Impact of Concomitant Drugs Providing Cytochrome P450 1A2 Modification-
复制标题
DOI：
10.1248/yakushi.12-00222
复制
发表时间：
2013-02-01
影响因子：
0.3
通讯作者：
Kohda, Yukinao
中科院分区：
文献类型：
--
作者：
Momo, Kenji;Homma, Masato;Kohda, Yukinao
通过回顾性调查处方相关病历，研究了替扎尼定与细胞色素P450 1A2抑制剂（可能改变替扎尼定的肝脏代谢）的药物相互作用。1563例在筑波大学医院接受替扎尼定治疗的患者进行了调查。其中，713例患者（45.6%）接受替扎尼定和CYP1A2抑制剂（37种药物）联合给药治疗。与未接受CYP1A2抑制剂的患者相比，接受替扎尼定和CYP1A2抑制剂联合治疗的患者的特征为老年、患有多种疾病、长期服用大量合并用药（超过10种药物）。在100例同时给予替扎尼定和8种CYP1A2抑制剂的患者中检查了替扎尼定诱导的不良反应。不利影响（例如，困倦：10例患者;低血压：9例患者;低心率：在CYP1A2抑制剂联合给药后8 ± 10天，在23例患者（23%）中观察到9例患者）。发生替扎尼定不良反应的患者年龄较大（64.3 ± 9.8岁vs. 57.5 ± 18.1岁，p
The drug-drug interactions of tizanidine and cytochrome (CYP) P450 1A2 inhibitors, which potentially alter the hepatic metabolism of tizanidine, were investigated by retrospective survey of medical records with regard to prescription. One thousand five hundred sixty-three patients treated with tizanidine at University of Tsukuba Hospital were investigated. Of those, 713 patients (45.6%) were treated with coadministration of tizanidine and CYP1A2 inhibitors (37 drugs). The patients who received a combination of tizanidine and CYP1A2 inhibitors were characterized as elderly, having multiple diseases, and taking a large number of comedications (over 10 drugs) for a long period as compared with the patients who did not receive CYP1A2 inhibitors. Tizanidine-induced adverse effects were examined in 100 patients treated with coadministration of tizanidine and 8 CYP1A2 inhibitors. Adverse effects (e.g., drowsiness: 10 patients; low blood pressure: 9 patients; low heart rate: 9 patients) were observed in 23 patients (23%) 8 +/- 10 days after CYP1A2 inhibitors were coadministered. The patients with tizanidine-induced adverse effects were of older age (64.3 +/- 9.8 vs. 57.5 +/- 18.1 years, p